【24h】

Diagnostics of primary cutaneous lymphomas

机译:诊断主要皮肤淋巴瘤

获取原文
获取原文并翻译 | 示例
       

摘要

Primary cutaneous lymphomas can be diagnosed when the clinical symptoms, histology, immunohistology and molecular biological changes are characteristic of primary cutaneous T or B-cell lymphomas; however, in many cases not all of the changes are typical of a primary cutaneous lymphoma especially in the early stages; therefore, the diagnosis of a primary cutaneous lymphoma can be a challenge. This is especially true for the Sezary syndrome, which can initially prove to be difficult to differentiate from reactive erythroderma; therefore, the main focus of this review is the diagnostics of Sezary syndrome. The review also summarizes the clinical heterogeneity and describes the classical histological and immunohistochemical changes for the diagnosis of Sezary syndrome. Recent data from different multicenter, international studies by the cutaneous lymphoma task force of the European Organisation for Research and Treatment of Cancer (EORTC) on dermatological alterations of the skin and the detection of Sezary cells in blood are addressed. The detection of Sezary cells in the blood still remains a challenge despite improved molecular boiological and cytogenetic characterization of tumor cells. The latest studies of the EORTC group particularly identified CD158k, MYC, MNT, DNM, TWIST1, EPHA4 and PLS3 as valuable markers for the differentiation of reactive erythroderma but which are not yet part of the standard diagnostics of Sezary syndrome. Further studies are required to see if these markers can be used in the routine clinical application.
机译:当临床症状,组织学,免疫组织学和分子生物学变化是初级皮肤T或B细胞淋巴瘤的特征时,可以诊断初级皮肤淋巴瘤;然而,在许多情况下,并非所有的变化都是典型的主要皮肤淋巴瘤,特别是在早期阶段;因此,初级皮肤淋巴瘤的诊断可能是一个挑战。对于Sezary综合征尤其如此,这最初可以证明难以区分反应性红霉菌剂;因此,本综述的主要重点是Sezary综合征的诊断。审查还总结了临床异质性,并描述了Sezary综合征诊断的经典组织学和免疫组织化学变化。来自不同多中心的最近数据,通过欧洲治疗和治疗癌症(EORTC)的皮肤淋巴瘤工作队进行皮肤淋巴瘤(EORTC)对皮肤的皮肤病的改变以及血液中SEZARY细胞的检测。尽管改善了肿瘤细胞的分子嗜好学和细胞遗传学表征,但血液中血液中的塞萨雷细胞的检测仍然是挑战。 EortC组的最新研究特别鉴定了CD158K,MyC,MNT,DNM,Twist1,EPHA4和PLS3作为反应性红斑分化的有价值标记,但尚未成为Sezary综合征标准诊断的一部分。需要进一步的研究来看看这些标志物是否可用于常规临床应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号